Pharma tariff relief likely short-lived with sector-specific duties on the horizon
Publishing timestamp: 2025-04-03 10:25:18
Summary
Pharmaceutical companies initially relieved to be exempt from reciprocal tariffs, but Trump administration considering investigation that could lead to import duties. Industry lobbying for phased approach to allow time to relocate manufacturing. Uncertainty causing stocks to dip and potential impact on supply chains and drug prices. Companies like Roche, Novo Nordisk, Novartis, and AstraZeneca considering additional U.S. investments. Novonesis expressing concerns about uncertainty affecting investment and consumer demand.
Sentiment: MIXED
Tickers: ROG-CH, NOV.N-CH, NVO, AZN-GB,
Keywords: biotechnology, bayer ag, roche holding ag, novo nordisk a/s, trade, business news, pharmaceuticals, bavarian nordic a/s, biotech and pharmaceuticals, novartis ag, astrazeneca plc,